CNS Market Research
A concise collection of reports on CNS, data includes Drug Discoveries, Disorders, Prospects and Opportunities.
Stay up-to-date with new products added to this categoryTitle ![]() | Date ![]() | Price ![]() |
|---|---|---|
| The Global Multiple Sclerosis Market 2009-2024 | Mar 2009 | £1,499 |
| Neurodegenerative Market Forecast to 2013 | Feb 2009 | £6,185 |
| Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders | Dec 2008 | £2,285 |
| Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies | Nov 2008 | £8,070 |
| Stakeholder Opinions: Restless Legs Syndrome Novel drugs to prosper as lifecycle management strategies fail | Nov 2008 | £4,635 |
| The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities | Sep 2008 | £2,340 |
| CNS Drug Discoveries: Depression | Aug 2008 | £595 |
| CNS Drug Discoveries: what the future holds 2008 FULL REPORT | Aug 2008 | £1,795 |
| CNS Drug Discoveries: Multiple Sclerosis | Aug 2008 | £595 |
| CNS Therapeutics | May 2008 | £2,410 |
| CNS Generic Drugs: Prospects and Opportunities to 2012 | Apr 2008 | £995 |
| Commercial Insight: CNS Market Overview Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors | Apr 2008 | £8,070 |
| Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022 | Oct 2007 | £1,499 |
| The CNS Market Outlook To 2012 | Oct 2007 | £1,755 |
| Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed | Sep 2007 | £7,600 |
| Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market | Sep 2007 | £6,000 |
| Commercial Insight: Epilepsy Companies Committed To The Cause Will Reap The Benefits | Sep 2007 | £7,600 |
| Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack | Sep 2007 | £7,600 |
| CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities | Jun 2007 | £995 |
| Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 | Jun 2007 | £1,999 |
| Pipeline Insight: Depression Novel drugs to grow third-line market | Mar 2007 | £6,950 |
| Innovations in CNS Novel therapeutics and future R&D strategies | Jan 2007 | £1,755 |
| Stakeholder Insight: Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice | Dec 2006 | £8,070 |
| Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines | Dec 2006 | £8,070 |
| Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries | Dec 2006 | £6,950 |
| CNS Drug Discoveries: Neurodegenerative Disorders | Nov 2006 | £795 |
| CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD) | Nov 2006 | £795 |
| Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share | Nov 2006 | £6,950 |
| Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors | Oct 2006 | £6,950 |
| Global Market for Sleep-Wake Disorders, 2005-2012, The Trends, Opportunities, and Insights in a High-Value CNS Therapy Area | Dec 2005 | £795 |
| Forecast Insight: Depression Generic induced brand erosion leads to market decline | Nov 1999 | £8,070 |
Filter Results by
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharma Chemicals
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us


previous












